Scilex Holding Company (NASDAQ:SCLX) saw its stock climb 6.9% after the U.S. Securities and Exchange Commission declared effective the registration statement for its planned merger with Semnur Pharmaceuticals.
The company, which specializes in non-opioid pain management treatments, confirmed that the Form S-4 tied to the merger between Denali Capital Acquisition Corp. (NASDAQ:DECAW) and Semnur, a majority-owned Scilex subsidiary, has successfully passed a key regulatory milestone.
Denali has scheduled an extraordinary general meeting for September 3, 2025, where shareholders will vote on the proposed merger. Only shareholders of record as of August 12, 2025, will be eligible to participate in the vote, which will take place in New York.
The merger is expected to close shortly after receiving shareholder approvals from both Denali and Semnur, along with completing other standard closing conditions outlined in the registration statement.
Although the combined company has applied to list its common stock and warrants on Nasdaq, final approval has not yet been granted. Should the listing application be denied, the securities of the merged company would continue trading on the OTC Markets after the business combination is completed.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management therapies for acute and chronic pain, as well as treatments for neurodegenerative and cardiometabolic diseases.
Scilex Holding Company stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.